No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MNMD240517P8000
- 0.03
- 0.000.00%
15min DelayTrading May 17 15:57 ET
0.00High0.00Low
0.00Open0.03Pre Close0 Volume0 Open Interest8.00Strike Price0.00Turnover403.51%IV-2.45%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.03Time Value100Contract SizeAmericanOptions Type-0.1981Delta1.0386Gamma272.33Leverage Ratio-1.5766Theta0.0000Rho-53.95Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
On CNBC's "Mad Money Lightning Round," Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA).On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna with an In-Line rating and an
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.Shares of Seritage Growth Properties (NYSE:SRG) fell sharply in today's pre-market trading after
Express News | Mind Medicine (MindMed) Inc. : Oppenheimer Cuts Target Price to $20 From $29
Mind Medicine Is Maintained at Buy by HC Wainwright & Co.
Mind Medicine Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35
HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price target from $75 to $35.
Comments
$Mind Medicine (MNMD.US)$ all work force buisness owner operators should invest into this companies products. this could not only benifit people with the disorders outlined in their descriptions but think about our work force in general I know for the agency I work for we have call ins all the time and generally speaking it's almost always the same people it isn't just my agency but national, jobs every wherewould benifit. so this company could help everyone every where! This company will ris...
$Mind Medicine(MNMD.US$ Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
1
1
$Mind Medicine(MNMD.US$
NEWS
MindMed Reports First Quarter 2024 Financial Results and Business Updates
MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks.
The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026.
MindMed is on track to begin its ...
NEWS
MindMed Reports First Quarter 2024 Financial Results and Business Updates
MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks.
The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026.
MindMed is on track to begin its ...
Read more